Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: An open-label study

Clinical Drug Investigation

Volumn 31, Issue 6, 2011, Pages 385-405

  Nasso, Elena Di ^a   Chiesa, Alberto ^b   Serretti, Alessandro ^b   De Ronchi, Diana ^b   Mencacci, Claudio ^a  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Depression; Duloxetine; therapeutic use; treatment

Indexed keywords

DULOXETINE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE DURATION; DOSE RESPONSE; DRUG WITHDRAWAL; EDUCATIONAL STATUS; FAMILY HISTORY; FEMALE; HAMILTON SCALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MARRIAGE; MENOPAUSE; MENTAL DEFICIENCY; MENTAL PATIENT; OBSESSIVE COMPULSIVE DISORDER; OCCUPATION; ONSET AGE; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PANIC; PATIENT COMPLIANCE; PREDICTION; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; REMISSION; SOMATIZATION; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; THIOPHENES; TREATMENT OUTCOME;

EID: 79955607008     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11588800-000000000-00000     Document Type: Article

References (58)

1. Kessler RC, Berglund P, Demler O. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095-105 (Pubitemid 37432885)
2. World Health Organization. The world health report 2002: reducing risks, promoting healthy life. Geneva; 2002
3. World Health Organization. Impact of disorders [online]. Available from URL: http://www.who.int/whr/2001/ chapter2/en/index3.html. 2001 [Accessed 2010 Apr 20]
4. Geddes JR, Freemantle N, Mason J, et al. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev 2000; (2): CD001851
5. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009 Feb 28; 373 (9665): 746-58
6. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006 Nov; 163 (11): 1905-17 (Pubitemid 44807782)
7. Kemp AH, Gordon E, Rush AJ, et al. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 2008 Dec; 13 (12): 1066-86; quiz 1087-8
8. Goodwin FK. Predictors of antidepressant response. Bull Menninger Clin 1993 Spring; 57 (2): 146-60 (Pubitemid 23148484)
9. Joyce PR, Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry 1989 Jan; 46 (1): 89-99 (Pubitemid 19038412)
10. Bagby RM, Ryder AG, Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci 2002; 27 (4): 250-7 (Pubitemid 34988905)
11. Krishnan KR. Comorbidity and depression treatment. Biol Psychiatry 2003 Apr 15; 53 (8): 701-6 (Pubitemid 39658486)
12. Zimmerman M, Chelminski I, McDermut W. Major depressive disorder and axis I diagnostic comorbidity. J Clin Psychiatry 2002; 63 (3): 187-93 (Pubitemid 34407076)
13. Papakostas GI, Fava M. Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialog Clinical Neurosci 2008; 10 (4): 439-51
14. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961 Jun; 4: 561-71
15. Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression: meta-analysis of published studies. Br J Psychiatry 2006 Jan; 188: 13-20 (Pubitemid 43021921)
16. Nelson EC, Cloninger CR. The tridimensional personality questionnaire as a predictor of response to nefazodone treatment of depression. J Affect Disord 1995 Oct 9; 35 (1-2): 51-7
17. Nelson E, Cloninger CR. Exploring the TPQ as a possible predictor of antidepressant response to nefazodone in a large multi-site study. J Affect Disord 1997 Jul; 44 (2-3): 197-200 (Pubitemid 27297858)
18. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006 Jan; 163 (1): 28-40 (Pubitemid 43050100)
19. Iosifescu DV, Nierenberg AA, Alpert JE, et al. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry 2003 Dec; 160 (12): 2122-7 (Pubitemid 39619604)
20. Papakostas GI, Petersen T, Iosifescu DV, et al. Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Res 2003 May 30; 118 (2): 183-8 (Pubitemid 36694432)
21. Rush AJ, Carmody TJ, Haight BR, et al. Does pretreatment insomnia or anxiety predict acute response to bupropion SR? Ann Clin Psychiatry 2005 Jan-Mar; 17 (1): 1-9 (Pubitemid 40471678)
22. Rush AJ, Batey SR, Donahue RM, et al. Does pretreatment anxiety predict response to either bupropion SR or sertraline? J Affect Disord 2001 Apr; 64 (1): 81-7 (Pubitemid 32268673)
23. Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007 Jul; 68 (7): 1062-70 (Pubitemid 47340327)
24. Thase ME, Pritchett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007 Dec; 27 (6): 672-6 (Pubitemid 351339455)
25. Schatzberg AF. Noradrenergic versus serotonergic antidepressants: predictors of treatment response. J Clin Psychiatry 1998; 59 Suppl. 14: 15-8 (Pubitemid 28462384)
26. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25 (6): 1171-80
27. Serretti A, Zanardi R, Mandelli L, et al. A neural network model for combining clinical predictors of antidepressant response in mood disorders. J Affect Disord 2007 Mar; 98 (3): 239-45 (Pubitemid 46149064)
28. Steiner M, Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 2000; 61 Suppl. 12: 17-21
29. Pae CU, Mandelli L, Kim TS, et al. Effectiveness of antidepressant treatments in pre-menopausal versus postmenopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. Biomed Pharmacother 2009 Mar; 63 (3): 228-35
30. Grigoriadis S, Robinson GE. Gender issues in depression. Ann Clin Psychiatry 2007 Oct-Dec; 19 (4): 247-55 (Pubitemid 350208795)
31. Mandelli L, Serretti A, Zanardi R, et al. Antidepressant response in the elderly. Psychiatry Res 2007 Jul 30; 152 (1): 37-44 (Pubitemid 47030682)
32. Meyers BS, Sirey JA, Bruce M, et al. Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study. Arch Gen Psychiatry 2002 Aug; 59 (8): 729-35 (Pubitemid 34847946)
33. Spillmann M, Borus JS, Davidson KG, et al. Sociodemographic predictors of response to antidepressant treatment. Int J Psychiatry Med 1997; 27 (2): 129-36 (Pubitemid 27407505)
34. Hirschfeld RM, Russell JM, Delgado PL, et al. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 1998; 59 (12): 669-75 (Pubitemid 29068312)
35. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2008 May; 15 (5): 473-500
36. Serretti A, Kato M, De Ronchi D, et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247-57 (Pubitemid 46328503)
37. Gupta S, Nihalani N, Masand P. Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders. Ann Clin Psychiatry 2007 Apr-Jun; 19 (2): 125-32 (Pubitemid 47035939)
38. Girardi P, Pompili M, Innamorati M, et al. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum Psychopharmacol 2009 Apr; 24 (3): 177-90
39. Howland RH, Wilson MG, Kornstein SG, et al. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry 2008 Oct-Dec; 20 (4): 209-18
40. Fava M, Martinez JM, Greist J, et al. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an openlabel outpatient study. Ann Clin Psychiatry 2007 Jul-Sep; 19 (3): 187-95 (Pubitemid 47345874)
41. Katz MM, Meyers AL, Prakash A, et al. Early symptom change prediction of remission in depression treatment. Psychopharmacol Bull 2009; 42 (1): 94-107
42. Fava M, Wiltse C, Walker D, et al. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2009 Mar; 113 (3): 263-71
43. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 Suppl. 20: 22-33; quiz 4-57 (Pubitemid 29001829)
44. First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV axis II personality disorders (SCIDII). New York (NY): Biometrics Research Department, New York State Psychiatric Institute, 1990
45. Brown GW, Harris TO. The Bedford College Life Events and Difficulties Schedule: directory of contextual threat ratings of events. Unpublished manuscript, Bedford College, University of London; 1978
46. Tollefson GD, Holman SL, Sayler ME, et al. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994 Feb; 55 (2): 50-9 (Pubitemid 24081821)
47. Schwab J, Warheit G, Holzer C. Suicide ideation and behaviour in a general population. Dis Nervous Syst 1972; 33: 745-8
48. Guy W. Clinical Global Impression: assessment manual for psychopharmacology. Washington, DC: US Department of Health Education and Welfare, 1976: 217-22
49. Gaynes BN, Magruder KM, Burns BJ, et al. Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression? Gen Hosp Psychiatry 1999 May-Jun; 21 (3): 158-67 (Pubitemid 29278010)
50. Hoehn-Saric R, Ninan P, Black DW, et al. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry 2000 Jan; 57 (1): 76-82 (Pubitemid 30035662)
51. Davidson JR, Meoni P, Haudiquet V, et al. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety 2002; 16 (1): 4-13 (Pubitemid 34977120)
52. Bakish D. The patient with comorbid depression and anxiety: the unmet need. J Clin Psychiatry 1999; 60 Suppl. 6: 20-4 (Pubitemid 29210627)
53. Breaux C, Hartlage S, Gehlert S. Relationships of premenstrual dysphoric disorder to major depression and anxiety disorders: a re-examination. J Psychosom Obstet Gynaecol 2000 Mar; 21 (1): 17-24 (Pubitemid 30311573)
54. Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 2001 Jul; 62 (7): 523-9 (Pubitemid 32703091)
55. JoffeH, Soares CN, Petrillo LF, et al. Treatment of depression and menopause-related symptoms with the serotoninnorepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry 2007 Jun; 68 (6): 943-50 (Pubitemid 47015497)
56. Blom MB, Spinhoven P, Hoffman T, et al. Severity and duration of depression, not personality factors, predict short term outcome in the treatment of major depression. J Affect Disord 2007 Dec; 104 (1-3): 119-26 (Pubitemid 350052321)
57. O'Leary D, Costello F, Gormley N, et al. Remission onset and relapse in depression: an 18-month prospective study of course for 100 first admission patients. J Affect Disord 2000; 57 (1-3): 159-71 (Pubitemid 30119968)
58. HamiltonM. The assessment of anxiety states by rating. Brit J Med Psychol 1959; 32: 50-5